11 results about "Active immunization" patented technology

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and / or booster vaccination in a subject.

This invention belongs to the field of animal model technology and discloses a method and system for constructing a NMOSD mouse model. The method includes extracting NMO-IgG from patient plasma replacement fluid, actively immunizing mice with an AQP4 p201-220 peptide emulsion, and injecting NMO-IgG to establish an NMOSD animal model. This invention uses active immunization with AQP4 p201-220 peptide combined with an antigen adjuvant, and then injects patient-derived NMO-IgG on this basis. Compared with other existing animal models, the characteristic clinical manifestations of NMOSD, including the detection of peripheral blood AQP4-IgG autoantibodies and the characteristic loss of AQP4 and GFAP proteins in the retina, optic nerve, and spinal cord, are more significant, more objectively reflecting the disease characteristics of NMOSD and providing a new research platform for related studies.

An immunogenic fusion protein for active immunization or a bivalent vaccine for treating atopic dermatitis (AD) in a subject and methods thereof. The immunogenic fusion protein comprises an IL31 polypeptide and at least one substance P polypeptide (SP). The present invention is particularly useful in the treatment and / or prevention of AD and symptoms associated with AD, including itching, in mammals.

This invention discloses an active immunization animal model of neuromyelitis optica spectrum disorder and its construction method. The construction method includes: extracting a membrane protein retaining the native conformational epitope of AQP4 from cells overexpressing AQP4-M23 as an immunogen; emulsifying the immunogen with an adjuvant and then actively immunizing non-human mammals to induce the production of autoantibodies against the AQP4 conformational epitope, thereby constructing an active immunization animal model of neuromyelitis optica spectrum disorder. This invention uses an AQP4 membrane protein rich in conformational epitopes as an immunogen, overcoming the limitation of traditional linear peptides in inducing pathogenic autoantibodies in wild-type mice. It successfully constructs an active immunization animal model capable of mimicking the core pathological features of human neuromyelitis optica spectrum disorder (including AQP4 loss and astrocyte damage), providing an important experimental platform for research on the pathogenesis of neuromyelitis optica spectrum disorder and drug screening.

The application discloses a short peptide for TRPM7 channel, a vaccine and pharmaceutical application of the short peptide for preventing and treating atrial fibrillation, and belongs to the technical field of biological medicine. The short peptide can be coupled with a carrier KLH by a glutaraldehyde coupling method to prepare a conjugate, and the conjugate is supplemented with an adjuvant to form a vaccine. The vaccine can induce the body to produce high-specificity and high-titer antibodies through active immunization, the antibodies can block the TRPM7 channel, inhibit calcium influx of atrial muscle cells and atrial fibroblasts, reduce calcium overload of cytoplasm, inhibit atrial electrical remodeling and tissue remodeling, and prevent and treat atrial fibrillation. The application provides a pharmaceutical composition containing the short peptide, the conjugate and the adjuvant, and a polyclonal antibody obtained by immunizing a non-human animal with the vaccine. Compared with existing chemical drugs, the application has the advantages of high targeting, long-acting, good safety, low price and the like, provides a new active immunotherapy strategy for atrial fibrillation patients, and has a wide clinical transformation prospect.

The invention provides an antigen epitope peptide of FimA of klebsiella pneumoniae. The antigen epitope peptide comprises an antigen dominant epitope with an amino acid sequence of SEQ ID NO: 19. The active immunization of the antigen potential epitope peptide coupling protein provided by the invention has the effect of preventing klebsiella pneumoniae infection, and can be used for preparing high-efficiency, low-toxicity and high-safety FimA-based medicines for preventing klebsiella pneumoniae infection.

The invention discloses a brucea javanica extract-cordycepin HPV (human papillomavirus) attenuated preparation as well as a preparation method and application thereof, and particularly relates to the technical field of antiviral preparations and gynecological medical treatment. The buccal tablet is prepared from the following components: 5%-15% of a brucea javanica extract, 0.3%-1.0% of cordycepin, 1%-3% of a surfactant, 2%-5% of a penetration enhancer, 0.5%-2% of a thickening agent, a pH regulator and the balance of purified water, the dosage of the pH regulator is a dosage for stabilizing the pH value of the preparation in a range of 4.0-6.5. Through pharmacological synergy of the brucea javanica extract and the cordycepin, a breakthrough of dual effects of direct virus resistance and active immune regulation is realized, the virus load is rapidly reduced, and the immune microenvironment of HPV persistent infection is fundamentally reversed by enhancing the self-cleaning capability of the body, so that the immune effect of the human body is improved. Through cooperation of double strategies of physical particle size optimization and chemical penetration enhancement, it is ensured that high-activity medicine components can efficiently permeate and be enriched in a focus part, and therefore the exertion speed and the action strength of the medicine effect are remarkably improved.

Described is a vaccine for use in actively immunising a subject against an infectious disease or a malignant disease, said vaccine comprising: (a) an antibody against an antigen correlated with said infectious disease or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen correlated with said infectious disease or malignant disease, wherein said Fc part is capable of binding a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activatory FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, FcγRIIIb, and inhibitory FcγRIIb; and Type II: neonatal FcR (FcRn) and cytosolic TRIM21. Moreover, described is a vaccine for use in actively immunising a subject against an HSV-associated disease; and (a) wherein said antibody is an anti-HSV antibody and said subject suffers from an acute HSV-associated disease, preferably an acute HSV infection; or (b) wherein in said Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen, the antigen correlates with an HSV-associated disease.

An immunogenic fusion protein is provided capable of conferring immunity to osteoarthritis in mammals, including canine, feline, and equine as well as methods of their use and preparation are also provided. More specifically, where an immunogenic fusion protein includes a first antigen derived from nerve growth factor, a second antigen that includes single or multiple repeat units of substance P or hemokinin-1, and a linker separating the first antigen from the second antigen, a nucleic acid encoding the immunogenic fusion protein, a vector comprising the nucleic acid; a host cell comprising the immunogenic fusion protein; a vaccine comprising the fusion protein; and a method of vaccination against osteoarthritis or osteoarthritis associated pain in dogs.

The present invention provides a method for labeling a biological tissue by immuno-electron microscopy, and specifically, the present invention provides a method for performing immuno-electron microscopy labeling on a tissue sample. The immuno-electron microscopy labeling is pre-embedding immuno-electron microscopy labeling, and the immuno-electron microscopy labeling is performed under the action of an electric field. Compared with a conventional antibody molecule diffusion-based method (referred to as a passive immuno-labeling method), the present invention solves the problem of an excessively long labeling time in pre-embedding immuno-electron microscopy technology by means of an external electric field-assisted antibody molecule diffusion technique (referred to as an active immuno-labeling method). Rapid immuno-electron microscopy labeling can be implemented, and an ultrastructure of a biological tissue can be protected.

The present disclosure relates to multivalent vaccine compositions and their use in protecting pigs and progeny thereof from infection with E. coli, Clostridium spp, porcine parvovirus, and E. rhusiopathie, preferably with a new administration regimen for passive and active immunization of pigs and progeny thereof, as well as their use in protecting pigs and progeny thereof from infection with E. coli, Clostridium spp, porcine parvovirus, and E. rhusiopathie.